Mind the Gap: Will Digital Replace Clinical?

It is a reflex we never had to learn. We close what is open and bandage what is torn. The mind does this too, quietly and without permission. Where knowledge is missing, it fills in, and the filling feels exactly like knowing.

Your patient arrives with their skin care routine already “vetted” by ChatGPT, which organized them into a tidy morning and evening regimen. It looked authoritative. It read like a plan. What it could not do, at any step, was clinically analyze their skin.

You have met many versions of this patient. The at-home microneedler who rolled their face and then applied a viral serum never meant to go past the barrier, now presenting with papules. The parent of an 11-year-old asking whether the retinol and glycolic products their child bought after a haul video are appropriate for a face that has not finished growing. The apple cider vinegar devotee with a predictably stripped barrier, or the beef tallow convert whose "ancestral" moisturizer is aggravating acne-prone skin. Each of them did the research. Each watched hours of content, whether based in evidence or not. What none of them received, anywhere in that pipeline from feed to chatbot to bathroom shelf, was an assessment of the actual skin in question.

The disconnect is not really about any single ingredient. It is about endpoints: the endpoint for the influencer is more followers, and for the clinician, it is clinical improvement. A recommendation optimized for engagement favors the dramatic. A recommendation optimized for outcomes favors slow, steady gains in skin health, and it requires the one thing neither an algorithm nor a chatbot can do: assess the individual patient.

The Discovery Phase

Here is the encouraging part. Patients are turning to social media primarily to discover specific products, not to replace their physician's judgment, and they still defer to clinical guidance when the two conflict. The data bear this out. In a cross-sectional survey of acne patients, two-thirds had sought information from influencers, mostly to learn about specific products, yet 81% reported "definite trust" in their dermatologist versus 2% for social media influencers, and 97% said they would defer to their dermatologist if that guidance contradicted what they had seen online.¹

Patients are not choosing influencers over clinicians. They use social platforms as a discovery layer before the appointment begins, and they bring what they found into the room. In my consultations, that is an advantage: the patient has already invested attention in the subject, so the conversation starts further along.

There is a second, quieter force behind this behavior: access. Specialist and dermatologic care is not evenly distributed. Wait times for a new dermatology appointment stretch for months in much of the country, and some regions have no local dermatologist at all. For a patient facing a long wait, an out-of-pocket cost, or no specialist within driving distance, social media is not competing with expert care. It is filling a vacuum. That patient is not bypassing the clinician so much as improvising in the clinician's absence.

And the appetite for expertise is there. University of Innsbruck survey data found that patients who followed clinician-authored content were more than twice as likely to keep a consistent routine, and a clear majority wished they saw more of it.² A separate survey identified distrust of the industry, not of physicians, as a leading barrier to care.³ Patients are not rejecting expertise. They are underexposed to it.

Which brings us back to the question in the title of this article. Will digital replace clinical? Patients are already answering that, and the answer is no. But the uncomfortable truth sits underneath it: digital does not have to replace clinical to displace it. It only has to be present when we are not. Clinicians long avoided social media out of concern for being equated with influencers, and that caution created the vacuum a mind fills with whatever is nearest.

The answer is not to compete on the algorithm's terms. It is to meld the two. Assessment, tailoring, and accountability for outcomes do not transfer to a feed, and they never will. Education does. If clinicians do not supply it, someone with far less training already is.

So the patient who arrives with a celebrity-endorsed serum is not necessarily skeptical of clinical expertise. More often they are trying to participate in their own care with the information, and the access, available to them. Treating that as an opportunity opened by curiosity rather than an error to be corrected keeps the conversation, and the patient, in the room. The bigger question is this: what the patient actually wants from their skin, what their skin actually needs, and why the two are best sorted out in front of someone who can assess them.

Ingredient Transparency as the Pivot

One of the more useful pivots in a consultation is redirecting from brand to ingredient. Consumer research supports this: a majority of skin care consumers now research ingredients before purchase, and many want brands and clinicians to explain in plain terms what an ingredient does.⁴

Asking your patient together, "what's actually in this?" respects that the patient came in informed, and it moves the conversation onto ground where clinical training carries the most weight: sourcing, formulation, and appropriate use.

Few categories generate more curiosity, or more confusion, than growth factor skin care. Market analysts have noted a sharp uptick in consumer conversation around biotech-derived skin care over the past year, a sign that this corner of the industry is outpacing patient education.⁵

Regenerative aesthetics is a central pillar of our practice, so our patients tend to arrive already curious. Consultations frequently cover growth factors, exosomes, and PDRN, which much of the public knows as the "salmon sperm facial." That nickname is unfortunate, but useful. Humor lowers psychological resistance, and a patient who is laughing is not counterarguing with the information you are presenting.

The explanation I return to is this. If stem cells are the senders, growth factors are the messages, and exosomes are the messengers that carry them. As we age, our cells decline in their ability to produce and send those messages, and restoring that signaling toward normal levels can meaningfully improve skin appearance and function. Two questions follow, both clinical rather than cosmetic.

• Where was the message sent from? Sourcing determines the content of the signal. This is the difference between important mail and junk mail, and it is why the cell of origin matters more than the brand on the bottle. It is also why I pay close attention to tissue sourcing. Adipose-derived mesenchymal stem cells, such as those used by the brand FACTORFIVE, for example, are selected for their regenerative secretome rather than simply because they are stem cells.
• How was the message delivered? This is where the category most often overstates itself, and where we can be useful to patients. The 500 Dalton rule holds that absorption through the stratum corneum falls sharply above roughly 500 Da, approaching zero past that threshold.⁶ Growth factors are proteins of thousands to tens of thousands of Daltons; exosomes are vesicles measured in nanometers. Neither passively crosses an intact stratum corneum in meaningful quantity.⁷

This is not an argument against the category. It is an argument for honesty about delivery. The strongest applications pair these molecules with a controlled, deliberate breach of the stratum corneum, well established in the chemical peel literature: a pre-treatment step that disrupts the barrier and degreases the surface yields more uniform penetration of whatever follows.⁸ The same principle governs regenerative delivery, and it is worth explaining to patients in plain terms: the message can be the finest ever written, but if it never gets past the door, it is never read.

I evaluate this the way I evaluate every product: scientific evidence, clinical validation, and, as a practice owner, financial transparency. For regenerative molecules, I add delivery vehicle as a fourth criterion. I invite a company to present, verify their claims independently, then trial the product on staff spanning a range of skin types. What stands out is a clinical team that knows its own evidence without overselling it. Which returns to the endpoint: followers, or outcomes.

Borrowing From Psychology, Not Marketing

Clinicians can learn something here from psychology and communication research. These are not sales tactics. They are ways to open a channel so information can actually land.

• Use curiosity to open the channel. "What drew you to this product?" opens more doors than "that won't do what you think it does."
• Tailor it to the patient in front of you. Anchor feedback to their actual skin, not the product's marketing. Personalized reasoning is harder to dismiss, and it is the one thing a chatbot structurally cannot offer.
• Offer a solution, not just a problem. Patients who hear only what is wrong with their routine disengage. Patients who leave with a next step follow through and framing it as a shared problem keeps you on the same side of the table.
• Use the moment as a bridge to your own content. If curiosity about an influencer product brought them to you, that same curiosity is an opening to your patient education materials.

Your Patients Can Ask You, or They Can Ask TikTok

The credibility gap is real, but it is narrower than it feels in the exam room, and it is not closing on its own. Patients still trust physicians more than any other source of skin care information, even while consuming content from creators.¹ The clinicians who benefit most from that trust meet curiosity with curiosity, use ingredient transparency as a bridge rather than a battleground, and treat every influencer-sourced product as a chance to teach rather than correct. As regenerative formulations become a larger share of what patients ask about, that framework will matter more, not less.

The mind will fill the gap either way. Digital will not replace clinical judgment, but it will keep filling the silence until clinicians step into it.

Candice Fortunato, MD, is a double board-certified physician, specializing in aesthetics, internal medicine, and pediatrics. She is currently the founder and medical director of [ Skin + Tonic ] in West Henderson, Nevada, and the past vice chair of pediatrics at Dignity Health Medical Center- St. Rose Siena Campus. She is also a brand ambassador for FACTORFIVE Skincare.

References

1. Bal ZI, Karaosmanoglu N, Temel B, Orenay OM. Trust in dermatologists versus social media influencers among acne patients. Cureus. 2025;17(5):e83930. doi:10.7759/cureus.83930

2. Lammer J, Wanner M, Bellmann P, et al. Integrating social media into modern dermatology: a cross-sectional study. J Dtsch Dermatol Ges. 2026;24(5):620-625. doi:10.1111/ddg.15911

3. Almudimeegh A, Almukhadeb E, Nagshabandi KN, et al. The influence of social media on public attitudes and behaviors towards cosmetic dermatologic procedures and skin care practices: a study in Saudi Arabia. J Cosmet Dermatol. 2024;23(8):2686-2696. doi:10.1111/jocd.16324

4. Witherington, A. Trends Shaping the Future of the Skincare Industry. Mintel. 2025. https://www.mintel.com/insights/beauty-and-personal-care/trends-shaping-the-future-of-the-skincare-industry/

5. Kitzmiller, C. US Ingredient Trends in Beauty Report 2025. Mintel. 2025. https://store.mintel.com/report/us-ingredient-trends-in-beauty-market-report

6. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol. 2000;9(3):165-169. doi:10.1034/j.1600-0625.2000.009003165.x

7. Moradi A, Bhatia AC, Behr K, Napekoski K, Foldvari M. In Vivo and Ex Vivo Evaluation of a Novel Method for Topical Delivery of Macromolecules Through the Stratum Corneum for Cosmetic Applications. Dermatol Surg. 2025;51(4):403-408. doi:10.1097/DSS.0000000000004504

8. Soleymani T, Lanoue J, Rahman Z. A practical approach to chemical peels: a review of fundamentals and step-by-step algorithmic protocol for treatment. J Clin Aesthet Dermatol. 2018;11(8):21-28.